Auris Medical Holding AG (NASDAQ: EARS) Q2 2020 earnings call dated Sep. 17, 2020. Corporate Participants: Thomas Meyer -- Chief Executive Officer
Auris Medical Holding AG (EARS) Q2 2020 Earnings Call Transcript
Categories
Biotechnology
Applied Genetic Technologies Corp. (AGTC) Q4 2020 Earnings Call Transcript
Applied Genetic Technologies Corp. (NASDAQ: AGTC) Q4 2020 earnings call dated Sep. 09, 2020 Corporate Participants: Sue Washer -- President and Chief Executive Officer
Ascendis Pharma A/S (ASND) Q2 2020 Earnings Call Transcript
Ascendis Pharma A/S (NASDAQ: ASND) Q2 2020 earnings call dated Aug. 27, 2020 Corporate Participants: Scott T. Smith -- Senior Vice President and Chief
Palatin Technologies Inc. (PTN) Q4 2020 Earnings Call Transcript
Palatin Technologies Inc (NYSEAMERICAN : PTN) Q4 2020 earnings call dated Sep. 28, 2020 Corporate Participants: Carl Spana -- President and Chief Executive Officer
What makes CVS Health a better investment option than Walgreens
https://www.youtube.com/watch?v=WOSh4S0zUds For healthcare systems across the world, currently, the first priority is to find an effective treatment for coronavirus, at a time
AnPac Bio-Medical Science Co., Ltd (ANPC) Q2 2020 Earnings Call Transcript
AnPac Bio-Medical Science Co., Ltd (NASDAQ: ANPC) earnings call dated September 10, 2020 Corporate Participants: Phil Case -- Marketing and Investor Relations Chris Yu -- Co-Founder
BeyondSpring Inc. (BYSI) Q2 2020 Earnings Call Transcript
BeyondSpring Inc. (NASDAQ: BYSI) Q2 2020 earnings call dated Sep. 03, 2020 Corporate Participants: Scott Eckstein -- Vice President Lan Huang -- Co-Founder, Chairman & Chief
Illumina (ILMN) is uniquely placed to offer long-term returns. Here’s why
Illumina, Inc. (NASDAQ: ILMN), a pioneer in genome sequencing technology, has strived to strengthen its unique position in the healthcare sector through
Silence Therapeutics PLC (SLN) Q2 2020 Earnings Call Transcript
Silence Therapeutics PLC (LON: SLN) Q2 2020 earnings call dated Sep. 14, 2020 Corporate Participants: Gem Hopkins -- Head of Investor Relations and Corporate
Avid Bioservices, Inc. (CDMO) Q1 2021 Earnings Call Transcript
Avid Bioservices, Inc. (NASDAQ: CDMO) Q1 2021 earnings call dated Sep. 01, 2020 Corporate Participants: Tim Brons -- Investor Relations Nicholas Green -- President & Chief
Aimmune Therapeutics Inc (AIMT) Q2 2020 Earnings Call Transcript
Aimmune Therapeutics Inc (NASDAQ: AIMT) Q2 2020 earnings call dated July 30, 2020 Corporate Participants: DeDe Sheel -- Vice President of Investor Relations
Should you buy Liminal BioSciences (LMNL) stock?
So far, COVID-19 has claimed more than 800,000 lives all over the world. The biomedical community is rigorously working on finding an
CureVac (CVAC): Another COVID-19 stock that attracted investors
In recent times, investors have been betting on the biotech companies that are in the race to develop the COVID-19 vaccine. The
Is Altimmune (ALT) stock a buy right now?
A lot of stocks in the biotech space have skyrocketed this year after their announcements and advances in finding a vaccine or
Novavax (NVAX) stock tumbles despite beating bottom line estimates in Q2
After Novavax (NASDAQ: NVAX) reported its progress on developing the COVID-19 vaccine at the end of February, the shares of the company
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2020 Earnings Call Transcript
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Q2 2020 earnings call dated Aug. 11, 2020 Corporate Participants: Glenn Schulman -- Senior Vice President, Corporate Communications and
Sage Therapeutics Inc (SAGE) Q2 2020 Earnings Call Transcript
Sage Therapeutics Inc (NASDAQ: SAGE) Q2 2020 earnings call dated August 10, 2020 Corporate Participants: Jeff Boyle -- Senior Director of Investor Relations Jeff
Novavax Inc. (NVAX) Q2 2020 Earnings Call Transcript
Novavax Inc (NASDAQ: NVAX) Q2 2020 earnings call dated Aug. 10, 2020 Corporate Participants: Silvia Taylor -- Senior Vice President, Investor Relations and Corporate
Novavax (NVAX) tops Q2 2020 bottom line targets, misses revenue views
Novavax (NASDAQ: NVAX) reported a loss of $17.5 million or $0.30 per share for the second quarter of 2020. Revenue jumped to
Moderna, Inc. (MRNA) Q2 2020 Earnings Conference Call Transcript
Moderna Inc. (NASDAQ: MRNA) Q2 2020 earnings call dated Aug. 05, 2020 Corporate Participants: Lavina Talukdar -- Head of Investor Relations Stephane Bancel -- Chief Executive
Moderna impresses on the financial side as well in Q2
Moderna, Inc., (Nasdaq: MRNA), a prime contender in Covid-19 vaccine research, on Wednesday, reported second-quarter financial results that smashed past analysts’ estimates.